Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial
건강한 지원자와 COVID-19 환자에 대한 메플라주맙의 안전성 및 효능: 무작위 1상 및 탐색적 2상 시험
Clinical Trial
Published on
Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, SARS, 비임상, 임상, 진단, 치료제,
Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, SARS, 비임상, 임상, 진단, 치료제,
[키워드] abstracts
accelerate
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
anti-CD147
antibody
assigned
biodistribution study
blocking
C max
cardiac blood–pool ratio
CD147
Cohort
cohorts
conducted
control group
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 patient
COVID-19 patients
COVID-19 pneumonia
determine
discharged
dosage
double-blinded
Efficacy
eight
enrolled
evaluate
Evidence
exploratory phase 2
exploratory phase 2 study
healthy subjects
healthy volunteer
healthy volunteers
hospitalized patient
humanized
IgG
in vitro
incidence
indicated
Infection
involved
lung
lung tissue
Meplazumab
meplazumab treatment
monoclonal antibody
Patient
patients
Peripheral blood
pharmacokinetic characteristics
pharmacokinetics
Phase 1
phase 1 study
phase 1 trial
Phase 2
Placebo
placebo-controlled
Pneumonia
positive
Prevent
Randomized
reached
recent
receptor
reduced
respiratory
Safety
safety profile
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 replication
serum
severe acute respiratory syndrome Coronavirus
severity
significantly
subject
suppress
TEAE
titer
Tolerability
Tolerance
treatment-emergent adverse event
Trial
virus
[DOI] 10.1038/s41392-021-00603-6 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1038/s41392-021-00603-6 PMC 바로가기 [Article Type] Clinical Trial